Creating a New Therapy (IND Submission)
IND Submission: Asking for Permission
At the end of all of this work, the developers think that the drug is ready to be tested in humans.
They can make it in a uniform manner in a form that can be given to people. They know a range of doses that are predicted to be safe in humans, and know that there are doses in this range that would be expected to have a therapeutic effect. They know how to administer the drug to participants and what markers to look for to see if it is having an effect. They have a feasible trial design, patients who want to take part and clinicians willing to run the trial.
At this point, the developer has the data that is needed to ask the FDA for approval to move forward.
If all this data is approved by the FDA, the drug will be allowed to start trials. That’s when it gets exciting — what happens to the drug in a human being? Will it work?Next: Clinical Trial
- Grants at a Glance
- Research Grants
- Creating a New Therapy
- What We've Achieved
- MDA Venture Philanthropy
- MDA Annual Conference
- 2019 Clinical & Scientific Conference
- 2018 Clinical Conference
- MOVR Data Hub
- Newborn Screening for Neuromuscular Diseases
- Cost of Illness of Neuromuscular Diseases in the US
- Medical Education for Health Care Providers
- Contact Our Research Team